ELA Pharma Cell Necrosis Treatment Patent EP4005569A2
Summary
The European Patent Office granted Patent EP4005569A2 to ELA Pharma Ltd covering pharmaceutical compositions for treating and preventing cell or tissue necrosis. The patent specifically targets cathepsin C and related enzymes CELA1 and CELA3A, with potential applications in neurological conditions (A61P25/28), cardiovascular conditions (A61P9/10), and metabolic disorders (A61P43/00). The granted patent covers designated contracting states including all major EU member states.
What changed
EPO granted Patent EP4005569A2 to ELA Pharma Ltd for compositions specifically targeting cathepsin C, CELA1, and CELA3A enzymes for cell necrosis treatment. The patent claims multiple therapeutic applications including neurological disorders (A61P25/28), cardiovascular conditions (A61P9/10), and general metabolic protection (A61P43/00). The designated contracting states cover all major EU member states plus several EEA states.
Pharmaceutical and biotech companies developing competing therapies targeting similar enzymatic pathways in the EU should conduct freedom-to-operate analyses. Generic drug manufacturers and biosimilar developers may face patent barriers for related indications. Research institutions and drug developers working on cathepsin inhibitors should evaluate potential overlap with granted claims.
What to do next
- Assess freedom-to-operate implications for competing cell necrosis treatments in EU designated states
- Review patent claims for potential licensing or partnership opportunities
- Monitor for related patent family filings in other jurisdictions
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO
Publication EP4005569A2 Kind: A2 Apr 01, 2026
Applicants
ELA Pharma Ltd
Inventors
Nathan, Ilana, Khalfin, Boris
IPC Classifications
A61K 31/00 20060101AFI20260129BHEP C07D 233/44 20060101ALI20260129BHEP C12N 15/113 20100101ALI20260129BHEP A61P 25/00 20060101ALI20260129BHEP A61K 31/426 20060101ALI20260129BHEP A61K 31/415 20060101ALI20260129BHEP A61K 31/4178 20060101ALI20260129BHEP A61K 31/4196 20060101ALI20260129BHEP A61K 31/454 20060101ALI20260129BHEP A61K 31/496 20060101ALI20260129BHEP A61K 31/4045 20060101ALI20260129BHEP A61K 31/428 20060101ALI20260129BHEP A61K 31/536 20060101ALI20260129BHEP C07K 16/40 20060101ALI20260129BHEP A61P 9/10 20060101ALI20260129BHEP A61P 25/28 20060101ALI20260129BHEP A61P 39/00 20060101ALI20260129BHEP A61P 43/00 20060101ALI20260129BHEP A61K 31/167 20060101ALI20260129BHEP A61K 31/4439 20060101ALI20260129BHEP C07D 233/48 20060101ALN20260129BHEP C07D 265/22 20060101ALN20260129BHEP C07D 405/06 20060101ALN20260129BHEP C07D 417/12 20060101ALN20260129BHEP C07D 275/06 20060101ALN20260129BHEP C07D 277/42 20060101ALN20260129BHEP C07D 277/56 20060101ALN20260129BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Get daily alerts for EPO Patent Bulletin - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.